Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedWatch info for DTC ads

Executive Summary

Reps. Janice Schakowsky, D-Ill., and Rosa DeLauro, D-Conn., stress the need for FDA to include a toll-free number and Web site in TV drug ads at a media briefing April 2, following the same-day release of a Consumers Union petition. Consumers Union cites the agency's failure to complete a study on whether TV ads should contain MedWatch reporting information, initially due at the end of March. DTC provisions in the FDA Amendments Act require adverse event reporting information on print ads, though pending legislation by the representatives may subject TV ads to tighter regulations (1"The Pink Sheet," March 3, 2008, p. 10)

You may also be interested in...



Pfizer’s Lipitor Ad Campaign Is A Cautionary Tale For Industry

Controversy surrounding Pfizer's direct-to-consumer advertisements for Lipitor spotlight the inherent risks manufacturers continue to face when launching ad campaigns

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection. 

Torrent’s $245m Curatio Deal Gives It Pole Position In Fast-Growing Cosmetic Dermatology

Torrent’s $245m acquisition of Curatio Healthcare has moved it up a rank to No.7 in the overall Indian pharmaceutical market apart from making it the market leader in cosmetic dermatology. While it’s a pricey deal, factors like growing prevalence of skin diseases and shift towards e-commerce bode well for future revenue growth in a nascent market

Latest News
See All
UsernamePublicRestriction

Register

PS049484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel